125 results about "Connexin" patented technology

A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.

Disclosed are compositions and methods for modulating hemichannel function in a cell, tissue or organ. The invention also relates to useful screens for detecting such compounds, particularly those capable of modulating connexin phosphorylation. Further provided are therapeutic methods for preventing or treating conditions impacted by undesired hemichannel function in a mammal such as heart arrhythmia.

A method of controlling (e.g., influencing or affecting) connexin 43 expression in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. In some embodiments, controlling connexin 43 expression in a subject may effectively treat cardiac arrhythmia and/or cancerous and pre-cancerous cells in a subject. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ester functionality.

Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.

Methods and compositions comprising an anti-ostepontin agent and/or a PDGF receptor blocker or antagonist, alone or in combination with one or more anti-connexin agents, for example, one or more anti-connexin polynucleotides and/or one or more anti-connexin peptides or peptidomimetics, are provided for the promotion and/or improvement of wound healing and/or tissue repair, and for anti-scarring, anti-inflammatory, anti-fibrosis and anti-adhesion indications.

The present invention demonstrates a method for inhibiting O-linked protein glycosylation in a tissue or cell, comprising the step of contacting said tissue or cell with (Z)-1-[N-(3-Ammoniopropyl)-N-(n-propy- l)amino] diazen-ium-1,2-diolate or a derivative thereof. The present invention is also directed to a method of treating or inhibiting the onset of diabetes mellitis in an individual in need of such treatment, comprising the step of admininstering to said individual a pharmacological dose of a compound which inhibiting O-linked protein glycosylation in a tissue or cell of said individual. Further, the present invention provides a pharmaceutical composition, comprising (Z)-1-[N-(3-Ammoniopropyl)-N-(n-propyl)amino] diazen-ium-1,2-diolate and a pharmaceutically acceptable carrier or a derivative thereof.

The present invention relates to a treatment agent for a disease or a disorder caused by a reduction in corneal endothelial cells, comprising as an active component at least one nucleic acid molecule inhibiting the expression of a connexin 43 gene.

Methods and compositions for modulating the activities of connexins are provided, including, for example, for use for treatment of cardiovascular, vascular, neurological, for wounds and for other indications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication or prevention of hemichannel opening is desirable.

Provided herein are compositions and methods for use in treating or preventing macular degeneration in a subject.

The invention provides methods for establishing electrical coupling between cardionyocytes and recombinant cells which have been genetically engineered to express a gap junction protein, eg., Connexin protein such as Connexin 43 (CX43) protein, n invention is based on the discovery that genetic modification of skeletal muscle cells to express a recombinant connexin, enables the genetically modified cells to establish electrocommunication with cardiac cells via gap junctions. The recombinant connexin-expressing cells can be used for repair of cardiac issue and for treatment of cardiac disease by transplantation into cardiac tissue.

The inventions relate to compositions and articles of manufacture comprising connexin modulators, pannexin modulators, gap junction modulators, hemichannel modulators, and pannexin channel modulators and their use, alone or in combination, in treating ocular and other disorders.

Methods and compositions comprising combinations and uses of a first anti-connexin agent and a second anti-connexin agent, for example, one or more anti-connexin polynucleotides and one or more anti-connexin peptides or peptidomimetics, are provided for therapeutic use including uses for the promotion and/or improvement of wounds and wound healing and/or tissue repair.

Methods, compounds, compositions, kits and articles of manufacture comprising anti-connexin agents for treatment of orthopedic disorders, diseases, or conditions, and improving recoveries and outcomes of orthopedic procedures or surgeries.

The present invention provides compositions and methods for the detection and characterization of mutations associated with non-syndromic hearing impairment. More particularly, the present invention provides compositions, methods and kits for using invasive cleavage structure assays (e.g. the INVADER assay) to screen nucleic acid samples, e.g., from patients, for the presence of any one of a collection of mutations in the Connexin 26, or gap junction beta 2, gene associated with non-syndromic hearing loss.

The invention relates to moisturizing composition granules and a preparation method thereof. The moisturizing composition granules are characterized by being prepared from the following components in percentage by mass: 20-40% of a moisturizing activated composition, 25-60% of a lactic acid/glycolic acid copolymer, 4-25% of a polyglycerol emulsifier and 8-15% of chondrus crispus extract, wherein the moisturizing activated composition consists of codium tomentosum extract, salicornia herbacea extract, ulkenia amoeboida extract and eryngium maritimum callus extract in a mass ratio of (2-5):(1-3):(1-3):(3-5); the moisturizing activated composition is prepared into dry nano granules of which the average particle size is 300-800nm. The moisturizing composition granules simultaneously load the codium tomentosum extract, the salicornia herbacea extract, the ulkenia amoeboida extract and the eryngium maritimum callus extract, a moisturizing system of skin is established from four aspects, that is, promoting synthesis of natural moisturizing factors, promoting synthesis of tight connexin, promoting synthesis of aquaporins-3 and promoting synthesis of corium layer hyaluronic acid, long-lasting moisturizing of skin is achieved, and the moisturizing effect can last for 48 hours.

The invention provides methods for establishing electrical coupling between cardiomyocytes and recombinant cells which have been genetically engineered to express a connexin protein such as connexin 43 (Cx43) protein. The invention is based on the discovery that genetic modification of skeletal muscle cells to express a recombinant connexin, enables the genetically modified cells to establish electrocommunication with cardiac cells via gap junctions. The recombinant connexin-expressing cells can be used for repair of cardiac tissue and for treatment of cardiac disease by transplantation into cardiac tissue.

The invention provides connexin core sequence-containing amphiphilic polypeptide AcN-RADARADARADARADAGGDHLSDNYTLDHDRAIH-CONH2, wherein the amphiphilic polypeptide and the amphiphilic polypeptide with the structure of AcN-RADARADARADARADA-CONH2 are triggered by Ca2+or a cell culture medium DMEM-F12 to automatically form into a compound, i.e. a nanometer-grade fiber material, and the nanometer-grade fiber material is taken as a bracket of the bone mesenchymal stem cells, so that the biological behavior of the cells can be obviously improved, the degenerated intervertebral disc can be repaired, and the original height can be recovered.

The invention relates to a method for testing gap linking protein 26 gene GJB2 mutation related to hereditary hearing impairment, which completely enlarges GJB2 gene base boot sector, exon 1, exon 2 and shear zone by polymerase chain reaction; and then, DNA sequence is measured to detect whether GJB2 genetic mutation exists; the method of the invention can completely cover all the genetic mutation of the GJB2 gene base boot sector, the exon 1, the exon 2 and the shear zone, so that detectable rate of the GJB2 genetic mutation and diagnosis rate of hereditary hearing impairment related to the GJB2 gene are improved; compared with that sequence measurement is separately carried out on a GJB2 code area, the method is more comprehensive and reliable, so as to be beneficial to the diagnosis of hereditary hearing impairment.